Novartis Ag (NVS) Free Cash Flow Growth (3y) (2012 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 33.62% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -20.26% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 17.80% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 17.73% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 28.91% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 23.79% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 56.97% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 45.09% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 18.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.73% |
| Mar 31, 2026 | 8.78% |
| Dec 31, 2025 | 4.47% |
| Sep 30, 2025 | 11.90% |
| Jun 30, 2025 | 20.36% |
| Mar 31, 2025 | 26.94% |
| Dec 31, 2024 | 21.01% |
| Sep 30, 2024 | 7.79% |
| Jun 30, 2024 | 4.64% |
| Mar 31, 2024 | 1.60% |
| Dec 31, 2023 | 63.97% |
| Sep 30, 2023 | 17.97% |
| Jun 30, 2023 | -3.26% |
| Mar 31, 2023 | 4.16% |
| Dec 31, 2022 | 29.51% |
| Sep 30, 2022 | 0.16% |
| Jun 30, 2022 | 5.78% |
| Mar 31, 2022 | -10.89% |
| Dec 31, 2021 | 29.68% |
| Sep 30, 2021 | 6.69% |